New Targets and New Agents in High-Risk Multiple Myeloma.

Abstract excerpt

Advances in the treatment of multiple myeloma have resulted in dramatic improvements in outcomes for patients. The newly emerging profiling of mutations emerging as a consequence of large prospective sequencing studies such as the CoMMpass Study or other efforts from European investigators are not further helping to define the place and role for personalized medicine in myeloma. While mutations such as NRAS,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Immunomodulation
• Share to Cancer Vaccines
• Share to GTP Phosphohydrolases